AR082864A2 - Preparacion de compuestos de aminopirimidina - Google Patents

Preparacion de compuestos de aminopirimidina

Info

Publication number
AR082864A2
AR082864A2 ARP110103194A ARP110103194A AR082864A2 AR 082864 A2 AR082864 A2 AR 082864A2 AR P110103194 A ARP110103194 A AR P110103194A AR P110103194 A ARP110103194 A AR P110103194A AR 082864 A2 AR082864 A2 AR 082864A2
Authority
AR
Argentina
Prior art keywords
formula
group
aminopirimidine
compounds
preparation
Prior art date
Application number
ARP110103194A
Other languages
English (en)
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of AR082864A2 publication Critical patent/AR082864A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • C07D239/36One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Un método para preparar un compuesto de aminopirimidina que tiene la fórmula (1) donde R es un grupo hidrocarbilo, seleccionado de un grupo alquilo, cicloalquilo, aralquilo o un grupo arilo y cada uno de R1 y R2, independientemente, es un átomo de hidrógeno, un grupo alquilo, alquilsulfonilo, o un grupo arilsulfonilo, que comprende hacer reaccionar un compuesto de pirimidina 2-sustituido que tiene la fórmula (2) donde R es igual que anteriormente, y X es un átomo de halógeno o un grupo sulfoniloxi orgánico, con un compuesto de amina que tiene la fórmula (3) donde cada R1 y R2 es igual que anteriormente, en presencia de una base.
ARP110103194A 2001-07-13 2011-09-01 Preparacion de compuestos de aminopirimidina AR082864A2 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2001213417 2001-07-13
JP2001213418 2001-07-13
JP2001310900 2001-10-09
JP2001360339 2001-11-27
JP2002007015 2002-01-16
JP2002042076 2002-02-19

Publications (1)

Publication Number Publication Date
AR082864A2 true AR082864A2 (es) 2013-01-16

Family

ID=27554967

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP020102617A AR034772A1 (es) 2001-07-13 2002-07-12 Preparacion de los compuestos de aminopirimidina
ARP110103194A AR082864A2 (es) 2001-07-13 2011-09-01 Preparacion de compuestos de aminopirimidina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP020102617A AR034772A1 (es) 2001-07-13 2002-07-12 Preparacion de los compuestos de aminopirimidina

Country Status (28)

Country Link
US (4) US7304156B2 (es)
EP (1) EP1417180B1 (es)
JP (2) JP4359141B2 (es)
KR (1) KR100888408B1 (es)
CN (2) CN1301977C (es)
AR (2) AR034772A1 (es)
AT (1) ATE349431T1 (es)
AU (1) AU2002318041B2 (es)
BR (1) BR0211072A (es)
CA (1) CA2453505C (es)
CO (1) CO5560574A2 (es)
CY (1) CY1107551T1 (es)
DE (1) DE60217126T2 (es)
DK (1) DK1417180T3 (es)
EG (1) EG24848A (es)
ES (1) ES2278032T3 (es)
HK (1) HK1064384A1 (es)
HU (1) HUP0401248A3 (es)
IL (2) IL159741A0 (es)
IS (1) IS2399B (es)
MX (1) MXPA04000322A (es)
MY (1) MY133579A (es)
NO (1) NO326173B1 (es)
NZ (1) NZ531033A (es)
PL (1) PL366831A1 (es)
PT (1) PT1417180E (es)
SI (1) SI1417180T1 (es)
WO (1) WO2003006439A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011120D0 (en) 2000-05-09 2000-06-28 Avecia Ltd Process
NL1015744C2 (nl) 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
ATE349431T1 (de) 2001-07-13 2007-01-15 Astrazeneca Uk Ltd Herstellung von aminopyrimidinverbindungen
EP1323717A1 (en) 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
EP1375493A1 (en) 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
WO2004054986A2 (en) * 2002-12-16 2004-07-01 Astrazeneca Uk Limited Process for the preparation of pyrimidine compounds
GB0312896D0 (en) * 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) * 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0324791D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
GB0514078D0 (en) * 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
US8455640B2 (en) * 2006-05-03 2013-06-04 Msn Laboratories Limited Process for statins and its pharmaceutically acceptable salts thereof
ES2567171T3 (es) 2006-10-09 2016-04-20 Msn Laboratories Private Limited Nuevo procedimiento para la preparación de estatinas y sus sales farmacéuticamente aceptables
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process
CN101323597B (zh) * 2007-06-11 2012-09-05 安徽省庆云医药化工有限公司 4-(4-氟苯基)-6-异丙基-2-(n-甲基-n-甲磺酰氨基)嘧啶-5-甲醛的制备方法
CN101376647B (zh) * 2007-08-31 2010-12-08 中山奕安泰医药科技有限公司 一种用于合成瑞舒伐他汀中间体及瑞舒伐他汀的合成方法
WO2009150668A1 (en) * 2008-06-13 2009-12-17 Delhi University Dihydropyridimidinone compounds for the treatment of cardiovascular diseases and process for preparing the same
US8487105B2 (en) 2009-01-19 2013-07-16 Msn Laboratories Limited Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof
US8987444B2 (en) 2010-01-18 2015-03-24 Msn Laboratories Private Limited Process for the preparation of amide intermediates and their use thereof
EP2423195A1 (en) 2010-07-26 2012-02-29 LEK Pharmaceuticals d.d. Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof
CN101955463B (zh) * 2010-08-04 2012-01-04 重庆博腾制药科技股份有限公司 瑞舒伐他汀钙中间体的制备方法
CN102584717B (zh) * 2011-01-17 2014-12-10 浙江九洲药业股份有限公司 用于制备罗苏伐他汀的中间体及相关制备方法和用途
CN103483269B (zh) * 2012-06-13 2016-04-27 上海迪赛诺药业有限公司 瑞舒伐他汀钙及其中间体的制备方法
WO2013185309A1 (zh) * 2012-06-13 2013-12-19 上海迪赛诺药业有限公司 瑞舒伐他汀钙及其中间体的制备方法
CN103864697A (zh) * 2012-12-11 2014-06-18 润泽制药(苏州)有限公司 瑞舒伐中间体主链醇的制备方法
CN104059024B (zh) * 2014-06-16 2016-04-06 浙江大学 瑞舒伐他汀中间体的制备方法及中间体化合物
CN107428703B (zh) * 2015-01-23 2021-01-12 灿盛制药有限公司荷兰公司 用于制备他汀前体的改进的方法
CN104817505A (zh) * 2015-04-23 2015-08-05 南京博优康远生物医药科技有限公司 一种制备n-[4-(4-氟苯基)-5-羟甲基-6-异丙基-嘧啶-2-基]-n-甲基甲磺酰胺的方法
CN109912522B (zh) * 2017-12-12 2021-04-13 北京颖泰嘉和生物科技股份有限公司 制备三唑啉硫酮化合物的方法
CN109081815A (zh) * 2018-11-12 2018-12-25 甘肃农业大学 一种新型亲电试剂甲磺酸嘧啶酯的制备方法
CN111138369A (zh) * 2019-12-17 2020-05-12 上海雅本化学有限公司 瑞舒法他汀中间体的制备方法
BR112022019387A2 (pt) * 2020-03-27 2022-11-16 Dong A St Co Ltd Derivados de aminopirimidina e seu uso como moduladores de receptores de aril hidrocarbonetos
CN112174898B (zh) * 2020-11-06 2021-05-04 浙江宏元药业股份有限公司 一种连续氧化二氢嘧啶酮制备羟基嘧啶的新方法

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4645858A (en) * 1982-03-22 1987-02-24 G. D. Searle & Co. Pentanedioic acid derivatives
US4625039A (en) * 1983-12-21 1986-11-25 Sandoz Pharm. Corp. 4-trisubstituted silyl protected hydroxy-6-oxo-tetrahydropyran-2-yl-aldehyde intermediates
US4650890A (en) * 1984-04-03 1987-03-17 Sandoz Corp. Preparation of olefinic compounds and intermediates thereof
US4613610A (en) * 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4677211A (en) * 1984-06-29 1987-06-30 Sandoz Pharmaceuticals Corp. Preparation of lactones
US4957971A (en) * 1986-07-07 1990-09-18 Warner-Lambert Company Trans-6-(2-(N-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl)-or ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US5102893A (en) * 1986-07-07 1992-04-07 Warner-Lambert Company Trans-6-(2-(n-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl- or ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4808621A (en) 1986-07-07 1989-02-28 Warner-Lambert Company Trans-6-[2-(N-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl]- or ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
DE3739882A1 (de) * 1987-11-25 1989-06-08 Bayer Ag Substituierte hydroxylamine
DE3741508A1 (de) 1987-12-08 1989-06-22 Hoechst Ag Wasserloesliche disazoverbindungen, verfahren zu ihrer herstellung und ihre verwendung als farbstoffe
DE3741509A1 (de) * 1987-12-08 1989-06-22 Hoechst Ag Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte
GB2244706B (en) 1988-02-18 1992-07-15 Bristol Myers Co Preparation of antihypercholesterolemic tetrazole intermediates
EP0367895A1 (en) 1988-10-06 1990-05-16 Sandoz Ag Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
IE914005A1 (en) * 1990-12-14 1992-06-17 Zeneca Ltd Novel intermediates
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
US5278313A (en) * 1992-03-27 1994-01-11 E. R. Squibb & Sons, Inc. Process for the preparation of 1,3-dioxane derivatives useful in the preparation of HMG-COA reductase inhibitors
ATE158579T1 (de) * 1992-07-02 1997-10-15 Hoechst Ag Verfahren zur herstellung von (3r,5s)6-hydroxy- 3,5-0-isopropyliden-3,5-dihydroxy-hexansäure- tert.-butylester
JP3197971B2 (ja) 1993-03-01 2001-08-13 塩野義製薬株式会社 5−カルボアルコキシピリミジン誘導体の合成方法
SK60097A3 (en) 1994-11-16 1998-01-14 Synaptic Pharma Corp Dihydropyrimidines, pharmaceutical composition containing same and use thereof
DE19517186A1 (de) 1995-05-11 1996-11-14 Bayer Ag Verfahren zur Herstellung substituierter 2-Fluor-pyrimidine
FR2741620B1 (fr) 1995-11-28 1997-12-26 Oreal Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline
US6278001B1 (en) * 1995-11-28 2001-08-21 L'oréal Method for preparing (+) compactin and (+) mevinolin analog compounds having a β-hydroxy-δ-lactone grouping
CZ184098A3 (cs) 1995-12-14 1998-11-11 Merck And Co., Inc. Způsob výroby dihydropyrimidinonů
JP2001512724A (ja) 1997-08-05 2001-08-28 メルク エンド カムパニー インコーポレーテッド α1aアドレナリン受容体拮抗薬
JP4440476B2 (ja) * 1998-12-10 2010-03-24 株式会社カネカ シンバスタチンの製造方法
GB9903472D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
EP1193259A4 (en) 1999-06-23 2003-01-29 Ajinomoto Kk dihydropyrimidine
WO2001004336A1 (de) 1999-07-09 2001-01-18 Forschungszentrum Jülich GmbH Verfahren zur reduktion von keto-carbonsäuren und deren estern
WO2001004100A1 (en) * 1999-07-13 2001-01-18 Lonza Ag Process for preparing 2-amino-4-(4-fluorphenyl)-6-alkylpyrimidine-5-carboxylate
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
AU2000254249A1 (en) 2000-03-28 2001-10-08 Biocon India Limited Synthesis of (r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-
GB0011120D0 (en) * 2000-05-09 2000-06-28 Avecia Ltd Process
GB0011163D0 (en) 2000-05-10 2000-06-28 Astrazeneca Ab Chemical compound
US8374574B1 (en) 2000-07-06 2013-02-12 Motorola Mobility Llc Method and apparatus for storing a message for playback during a user-initiated emergency telephone call from a wireless device
NL1015744C2 (nl) * 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
PL367133A1 (en) * 2001-06-06 2005-02-21 Bristol-Myers Squibb Company Process for preparing chiral diol sulfones and dihydroxy acid hmg coa reductase inhibitors
SE0102299D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
CN101880227A (zh) 2001-07-06 2010-11-10 西巴特殊化学品控股有限公司 一种用于制备适合于制备他汀类衍生物的中间体化合物的方法及其中间体
ATE349431T1 (de) 2001-07-13 2007-01-15 Astrazeneca Uk Ltd Herstellung von aminopyrimidinverbindungen
CN1545502A (zh) 2001-08-22 2004-11-10 �������⻯ѧƷ�ع����޹�˾ 吲哚衍生物的制备方法
EP1323717A1 (en) * 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
US6835838B2 (en) 2002-01-28 2004-12-28 Novartis Ag Process for the manufacture of organic compounds
KR100511533B1 (ko) 2002-04-09 2005-08-31 임광민 키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법
US20050222415A1 (en) 2002-05-21 2005-10-06 Yatendra Kumar Process for the preparation of rosuvastatin
EP1375493A1 (en) * 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
SI1578733T1 (sl) 2002-12-10 2011-07-29 Ranbaxy Lab Ltd Postopek za pridobitev rosuvastatina
WO2004054986A2 (en) 2002-12-16 2004-07-01 Astrazeneca Uk Limited Process for the preparation of pyrimidine compounds
WO2004103977A2 (en) 2003-05-21 2004-12-02 Ciba Specialty Chemicals Holding Inc. Process for the preparation of pyrimidine derivatives
GB0312896D0 (en) * 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) * 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0321827D0 (en) * 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
DE10352659B4 (de) * 2003-11-11 2007-09-13 Ratiopharm Gmbh Verfahren zur Herstellung von Statinen und Tetrahydropyranonderivate zur Verwendung in dem Verfahren
WO2005054207A1 (en) * 2003-12-04 2005-06-16 Glenmark Pharmaceuticals Limited Process for the preparation of pyrimidine derivatives
EP1697338A2 (en) 2003-12-24 2006-09-06 Teva Pharmaceutical Industries Ltd. Process for preparation of statins with high syn to anti ratio
GB0406757D0 (en) 2004-03-26 2004-04-28 Avecia Ltd Process and compounds
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
CA2498978A1 (en) 2005-02-28 2006-08-28 Apotex Pharmachem Inc. An improved process for the preparation of atorvastatin and intermediates
GB0514078D0 (en) 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process
EP2314945B1 (en) 2008-10-29 2017-07-26 Mitsubishi Electric Corporation Air conditioner

Also Published As

Publication number Publication date
DK1417180T3 (da) 2007-04-10
MY133579A (en) 2007-11-30
EP1417180B1 (en) 2006-12-27
US20110160455A1 (en) 2011-06-30
CO5560574A2 (es) 2005-09-30
EG24848A (en) 2010-10-27
CN1301977C (zh) 2007-02-28
JP4359141B2 (ja) 2009-11-04
KR20040030051A (ko) 2004-04-08
HK1064384A1 (en) 2005-01-28
CY1107551T1 (el) 2013-03-13
JP2004536849A (ja) 2004-12-09
IL159741A (en) 2009-06-15
MXPA04000322A (es) 2005-09-08
US8614320B2 (en) 2013-12-24
JP5016583B2 (ja) 2012-09-05
JP2009167167A (ja) 2009-07-30
US20040176401A1 (en) 2004-09-09
CN1527821A (zh) 2004-09-08
PT1417180E (pt) 2007-03-30
SI1417180T1 (sl) 2007-04-30
HUP0401248A2 (hu) 2004-10-28
ATE349431T1 (de) 2007-01-15
US20120277432A1 (en) 2012-11-01
DE60217126D1 (de) 2007-02-08
ES2278032T3 (es) 2007-08-01
BR0211072A (pt) 2004-12-14
US7816528B2 (en) 2010-10-19
HUP0401248A3 (en) 2004-11-29
IS2399B (is) 2008-09-15
WO2003006439A1 (en) 2003-01-23
KR100888408B1 (ko) 2009-03-13
EP1417180A1 (en) 2004-05-12
NZ531033A (en) 2005-07-29
DE60217126T2 (de) 2007-10-04
IS7103A (is) 2004-01-12
US7304156B2 (en) 2007-12-04
PL366831A1 (en) 2005-02-07
NO326173B1 (no) 2008-10-13
NO20040122L (no) 2004-01-12
CA2453505A1 (en) 2003-01-23
US20080058520A1 (en) 2008-03-06
AR034772A1 (es) 2004-03-17
IL159741A0 (en) 2004-06-20
AU2002318041B2 (en) 2008-01-03
CN1763016A (zh) 2006-04-26
CN100349877C (zh) 2007-11-21
EP1417180A4 (en) 2004-10-27
US8222412B2 (en) 2012-07-17
CA2453505C (en) 2011-04-19

Similar Documents

Publication Publication Date Title
AR082864A2 (es) Preparacion de compuestos de aminopirimidina
AR047533A1 (es) Proceso para preparar carboxamidas 2-aminotiazol-5-aromaticas como inhibidores de la quinasa
ECSP055974A (es) Síntesis de cloruros de 4 amino-2-butenoil y su uso en la preparación de 3-ciano quinolinas
AR006720A1 (es) Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende
BR0206433A (pt) Composto, composição farmacêutica, processo para a prepapação de um composto, e, uso de um composto
MXPA03011039A (es) Nuevos compuestos heterociclicos, su preparacion y uso como medicamentos, particularmente como agentes anti-bacterianos.
CO5601018A2 (es) Derivados de n-fenil-2-pirimidin-amina
PT1294724E (pt) Compostos pirrolo (2,3-d ) pirimidina como agentes imunosupressivos
SE0100903D0 (sv) Compounds
AR049323A1 (es) Compuestos heterociclicos nitrogenados inhibidores de igf-1r y composiciones farmaceuticas que los componen.
AR031597A1 (es) Compuestos piperidinos,un proceso para su preparacion, composiciones farmaceuticas,y el uso de dichos compuestos para la fabricacion de un medicamento para uso como inhibidores ccr-3
SE0103710D0 (sv) Compounds
BR0317313A (pt) Processo para a preparação de um composto, e, composto
DK1706414T3 (da) Fremgangsmåde til fluorcytidinderivater
HRP20030610B1 (en) Process for the preparation of mesylates of piperazine derivatives
CO4970700A1 (es) Proceso para la preparacion de pirimidinas sustituidas
ES2050069B1 (es) Procedimiento para la obtencion de 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-il)piperidino)etil)-2-metil-6,7,8,9-tetrahidro-4h-pirido(1,2-a) pirimidin-4-ona.
CO5180536A1 (es) Inhibidores de proteasas catepsina
AR019661A1 (es) Procedimiento para la manufactura de compuestos de piridina-2,3-dicarboxilato y compuesto para su exclusivo uso en dicho procedimiento
CO5540311A2 (es) Derivados de pirimidina utiles como inhibidores de cox-2 selectivos
EE200300090A (et) Asendatud imidasopüridiinühendite valmistamise meetod
CO5231148A1 (es) Compuesros herbicidas derivados de la piridina-2,6- sustituida, procedimiento para prepararlos, las composiciones herbicidas que los contienen, el procedimiento de aplicacion de dichos compuestos y el uso de los mismos como herbicidas
DOP2001000226A (es) Proceso para preparar 2-(4-piridil) amino-6-dialqui- loxifenil-pirido [2,3-d] pirimidin-7-onas (process for preparing 2-(4-pyridil) amino-6-dialkyphenyl-pyrido 2,3-d]
CO5031252A1 (es) Compuestos
CO5140090A1 (es) Derivados de pirazol, su preparacion y su aplicacion en terapeutica

Legal Events

Date Code Title Description
FA Abandonment or withdrawal